Free Trial

Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics logo
$0.37 +0.04 (+10.52%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.39 +0.01 (+3.74%)
As of 07/7/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OVID vs. XBIT, ZNTL, SAVA, OKYO, JSPR, FBRX, CLLS, CLYM, CABA, and MCRB

Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include XBiotech (XBIT), Zentalis Pharmaceuticals (ZNTL), Cassava Sciences (SAVA), OKYO Pharma (OKYO), Jasper Therapeutics (JSPR), Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

Ovid Therapeutics vs. Its Competitors

XBiotech (NASDAQ:XBIT) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

In the previous week, XBiotech and XBiotech both had 1 articles in the media. XBiotech's average media sentiment score of 0.59 beat Ovid Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XBiotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ovid Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

XBiotech has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. XBiotech's return on equity of -21.14% beat Ovid Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -21.14% -19.55%
Ovid Therapeutics -4,562.23%-34.17%-25.34%

Ovid Therapeutics has a consensus target price of $3.13, indicating a potential upside of 735.56%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ovid Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 33.1% of XBiotech shares are owned by insiders. Comparatively, 13.1% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ovid Therapeutics has lower revenue, but higher earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotech$4.01M23.19-$38.53M-$1.29-2.36
Ovid Therapeutics$570K46.66-$26.43M-$0.35-1.07

XBiotech has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats XBiotech on 9 of the 16 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVID vs. The Competition

MetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$24.06M$2.91B$5.52B$9.02B
Dividend YieldN/A2.44%5.24%4.08%
P/E Ratio-1.0720.4427.2620.04
Price / Sales46.66190.07381.2593.27
Price / CashN/A41.7026.2128.59
Price / Book0.397.397.945.55
Net Income-$26.43M-$55.04M$3.17B$248.49M
7 Day Performance18.35%2.51%1.80%4.87%
1 Month Performance17.39%-0.21%1.28%6.63%
1 Year Performance-55.25%3.41%33.57%20.38%

Ovid Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVID
Ovid Therapeutics
4.2033 of 5 stars
$0.37
+10.5%
$3.13
+735.6%
-49.8%$24.06M$570K-1.0760Gap Up
High Trading Volume
XBIT
XBiotech
0.4619 of 5 stars
$2.97
+6.1%
N/A-46.5%$85.37M$4.01M-2.30100Positive News
Gap Up
ZNTL
Zentalis Pharmaceuticals
1.5518 of 5 stars
$1.16
-1.7%
$8.37
+621.3%
-67.1%$84.90M$67.43M-0.37160
SAVA
Cassava Sciences
3.8856 of 5 stars
$1.81
+3.4%
$54.50
+2,911.0%
-81.1%$84.54MN/A-1.2130
OKYO
OKYO Pharma
1.8292 of 5 stars
$2.57
+4.9%
$7.00
+172.4%
+135.0%$82.90MN/A0.007Positive News
JSPR
Jasper Therapeutics
3.3941 of 5 stars
$5.55
+1.1%
$59.25
+967.6%
-85.6%$82.47MN/A-1.0620News Coverage
Analyst Forecast
Gap Down
FBRX
Forte Biosciences
2.5394 of 5 stars
$12.93
+5.6%
$61.00
+371.8%
+55,480.0%$80.65MN/A-0.795
CLLS
Cellectis
3.0362 of 5 stars
$1.53
+5.2%
$4.00
+162.3%
-21.6%$80.60M$49.22M-1.77290
CLYM
Climb Bio
2.6152 of 5 stars
$1.24
+5.1%
$9.00
+625.8%
N/A$79.74MN/A0.009Positive News
CABA
Cabaletta Bio
1.5251 of 5 stars
$1.52
-3.2%
$14.43
+849.2%
-78.9%$79.67MN/A-0.6050Positive News
Gap Up
MCRB
Seres Therapeutics
3.5245 of 5 stars
$11.11
+22.1%
$73.67
+563.1%
-33.2%$79.46M$126.32M-2.42330Positive News
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OVID) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners